Advertisement

Mesangial Cell Hypertrophy by High Glucose Is Mediated by Downregulation of the Tumor Suppressor PTEN

  1. Lenin Mahimainathan1,
  2. Falguni Das1,
  3. Balachandar Venkatesan1 and
  4. Goutam Ghosh Choudhury123
  1. 1Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas
  2. 2Geriatric Research, Education and Clinical Center, San Antonio, Texas
  3. 3South Texas Veterans Health Care System, San Antonio, Texas
  1. Address correspondence and reprint requests to Goutam Ghosh Choudhury, Department of Medicine, Mail Code 7882, 7703 Floyd Curl Dr., San Antonio, Texas 78229-3900. E-mail: choudhuryg{at}uthscsa.edu

Abstract

Diabetic nephropathy is characterized early in its course by glomerular hypertrophy and, importantly, mesangial hypertrophy, which correlate with eventual glomerulosclerosis. The mechanism of hypertrophy, however, is not known. Gene disruption of the tumor suppressor PTEN, a negative regulator of the phosphatidylinositol 3-kinase/Akt pathway, in fruit flies and mice demonstrated its role in size control in a cell-specific manner. Here, we investigated the mechanism of mesangial hypertrophy in response to high extracellular glucose. We link early renal hypertrophy with significant reduction in PTEN expression in the streptozotocin-induced diabetic kidney cortex and glomeruli, concomitant with activation of Akt. Similarly, exposure of mesangial cells to high concentrations of glucose also decreased PTEN expression and its phosphatase activity, resulting in increased Akt activity. Expression of PTEN inhibited high-glucose–induced mesangial cell hypertrophy, and expression of dominant-negative PTEN was sufficient to induce hypertrophy. In diabetic nephropathy, the hypertrophic effect of hyperglycemia is thought to be mediated by transforming growth factor-β (TGF-β). TGF-β significantly reduced PTEN expression in mesangial cells, with a reduction in its phosphatase activity and an increase in Akt activation. PTEN and dominant-negative Akt attenuated TGF-β–induced hypertrophy of mesangial cells. Finally, we show that inhibition of TGF-β signal transduction blocks the effect of high glucose on PTEN downregulation. These data identify a novel mechanism placing PTEN as a key regulator of diabetic mesangial hypertrophy involving TGF-β signaling.

Footnotes

  • Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact

    • Accepted March 27, 2006.
    • Received October 11, 2005.
| Table of Contents
Advertisement